| |
| Saturday, Jun 01, 2013 08:59 PM PDT | |
| Today's Reuters Science News Headlines - Yahoo! News: | |
| | |
| Death toll rises to nine from Oklahoma tornadoes Saturday, Jun 01, 2013 08:59 PM PDT | Top |
| Glaxo drug shown to delay ovarian cancer relapse Saturday, Jun 01, 2013 09:08 AM PDT By Deena Beasley CHICAGO (Reuters) - A cancer drug sold by GlaxoSmithKline was shown in a clinical trial to extend by several months the length of time ovarian cancer patients lived without their disease worsening. The findings suggest that the oral drug, Votrient, could be used as a "maintenance" therapy for many ovarian cancer patients whose disease had returned after initial surgery and chemotherapy. "This is the first positive clinical trial for a targeted agent in ovarian cancer," said lead study author Dr. ... Full Story | Top |
| Rock guitarist May leads London march against badger cull Saturday, Jun 01, 2013 06:52 AM PDT | Top |
| Drug is a first to help patients with melanoma of the eye Saturday, Jun 01, 2013 04:33 AM PDT By Julie Steenhuysen CHICAGO (Reuters) - In his first few weeks as head of the melanoma group at Memorial Sloan-Kettering Cancer Center seven years ago, a young man walked into Dr. Gary Schwartz's office with a rare form of the skin cancer that affects the eye. "It was horrible. He died of metastatic disease. He was only 24. I promised him I would find a way to cure his cancer," recalls the physician-scientist of the patient who helped inspire his quest to find an effective treatment for uveal melanoma, which affects 2,000 to 3,000 patients each year. ... Full Story | Top |
| Amgen melanoma drug improved survival by 21 percent in interim look Saturday, Jun 01, 2013 04:32 AM PDT By Deena Beasley CHICAGO (Reuters) - Data from a pivotal trial of Amgen Inc's experimental melanoma therapy shows that it improved survival by 21 percent for patients with advanced forms of the deadly skin cancer compared with a standard white blood cell-boosting drug. Final survival results are not expected until later this year, but Wall Street has been awaiting the interim trial details to help assess the drug's commercial potential within a new market of promising melanoma treatments. ... Full Story | Top |
|

No comments:
Post a Comment